Skip to main content

Briefing Document

You are here

Drug-Resistant Tuberculosis Treatment & Access to Delamanid in South Africa

Delamanid is one of the first new medicines developed for DR-TB treatment in 50 years. The standard treatment duration is for the first six months of DR-TB treatment. The WHO issued interim guidelines on DLM use to treat MDR-TB in November 2014 and on its use in treating children and adolescents in 2016. Delamanid is also included in the 19th WHO Model List of Essential medicines.